LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Alkermes PLC

Abierto

SectorSanidad

29.28 -1.61

Resumen

Variación precio

24h

Actual

Mínimo

29.13

Máximo

29.45

Métricas clave

By Trading Economics

Ingresos

-124M

22M

Ventas

-123M

307M

P/B

Media del Sector

14.205

50.857

BPA

0.291

Margen de beneficios

7.329

Empleados

1,800

EBITDA

-168M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+35.81% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-906M

4.9B

Apertura anterior

30.89

Cierre anterior

29.28

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

170 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 jun 2025, 17:32 UTC

Principales Movimientos del Mercado

Lion Group Shares Climb on $600 Million Loan for Crypto Treasury

18 jun 2025, 23:55 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book Restructuring Loss Related to This Sale in 1Q

18 jun 2025, 23:53 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: NS Kote Is an Entity That Owns All of Company's Equity Stake in AM/NS Calvert

18 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book About Y230B Loss Related to Sale of NS Kote to ArcelorMittal

18 jun 2025, 23:50 UTC

Charlas de Mercado

Australian Uranium Stocks Tipped to Go Higher -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

18 jun 2025, 23:07 UTC

Charlas de Mercado

Fletcher Building Recovery May Be More Muted Than Thought -- Market Talk

18 jun 2025, 23:00 UTC

Charlas de Mercado

Smart Glasses Seen as Possible Future Agentic AI Platform -- Market Talk

18 jun 2025, 21:50 UTC

Charlas de Mercado

Argentina Poised To Become Significant LNG Exporter, Rystad Says -- Market Talk

18 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

18 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

U.S. Steel and Nippon Finalize Their 'Partnership.' What Comes After the Merger. -- Barrons.com

18 jun 2025, 20:32 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, Marvell, Sunrun, Nucor, Circle Internet, Korn Ferry, GMS, and More -- Barrons.com

18 jun 2025, 19:59 UTC

Charlas de Mercado

Oil Edges Up as Next Steps in Iran Conflict Eyed -- Market Talk

18 jun 2025, 19:42 UTC

Charlas de Mercado

Natural Gas Extends Gains for Fourth Session -- Market Talk

18 jun 2025, 19:40 UTC

Ganancias

Fed Holds Rates Steady and Keeps Door Open to Cuts -- 3rd Update

18 jun 2025, 18:47 UTC

Adquisiciones, fusiones, absorciones

Railroads Have Slashed Costs and Raised Prices. Why One CEO Now Favors a Merger. -- Barrons.com

18 jun 2025, 18:33 UTC

Charlas de Mercado

Fitch Says U.S. Fiscal Outlook Remains Challenging -- Market Talk

18 jun 2025, 18:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 jun 2025, 18:26 UTC

Charlas de Mercado

Nucor, Steel Dynamics Seen Diverging In Approach To Current Business Climate -- Market Talk

18 jun 2025, 18:15 UTC

Charlas de Mercado

Gold Stays Flat After Fed Decision -- Market Talk

18 jun 2025, 17:42 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Expects Related 2Q Gain of About $1.5B

18 jun 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Completes Acquisition of Nippon Steel's 50% Interest in AM/NS Calvert

18 jun 2025, 17:20 UTC

Ganancias

Credit Card Annual Fees Are Going Up. What It Means for the Stocks. -- Barrons.com

18 jun 2025, 16:52 UTC

Charlas de Mercado

Trump Awakens Canada On Need For Fewer Trade Barriers, Macklem Says -- Market Talk

18 jun 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel Completes Purchase of U.S. Steel After Reaching Security Deal With Trump Administration -- Update

18 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Alkermes PLC previsión

Precio Objetivo

By TipRanks

35.81% repunte

Estimación a 12 Meses

Media 40.43 USD  35.81%

Máximo 52 USD

Mínimo 30 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

9

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

170 / 381 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.